Skip to content

Tesaro hit by Clovis data

June 19, 2017

TESARO (NASDAQ: TSRO) is trading down 10.7% following positive phase 3 ARIEL3 trial data of rucaparib from competitor Clovis Oncology, Inc. (NASDAQ: CLVS).

Top line data showed the drug successfully achieved the primary endpoint of improved progression-free survival (PFS) by investigator review in each of the three populations studied. PFS was also improved in the rucaparib group compared with placebo by blinded independent central review (BICR), a key secondary endpoint.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: